MediPharm Labs Corp.
MEDIF
$0.0554
-$0.0046-7.67%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.31% | 12.56% | 24.86% | 30.89% | 31.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.31% | 12.56% | 24.86% | 30.89% | 31.70% |
| Cost of Revenue | 30.12% | 12.34% | 23.91% | 4.09% | -21.11% |
| Gross Profit | -8.41% | 12.99% | 26.88% | 135.10% | 3,370.80% |
| SG&A Expenses | -3.53% | -17.14% | 3.40% | -9.70% | -2.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -5.83% | -244.14% | -132.26% | -49.77% | -140.28% |
| Total Operating Expenses | 13.43% | -2.49% | 13.16% | -2.89% | -14.17% |
| Operating Income | -8.33% | 50.63% | 21.71% | 59.74% | 71.64% |
| Income Before Tax | 37.66% | 47.34% | 20.92% | 24.96% | 31.41% |
| Income Tax Expenses | -- | -- | -- | -2,940.91% | -4,511.36% |
| Earnings from Continuing Operations | 36.37% | 46.28% | 19.27% | 26.62% | 32.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.37% | 46.28% | 19.27% | 26.62% | 32.77% |
| EBIT | -8.33% | 50.63% | 21.71% | 59.74% | 71.64% |
| EBITDA | -38.74% | 59.80% | 29.37% | 70.96% | 81.71% |
| EPS Basic | 39.11% | 48.44% | 29.41% | 39.66% | 51.08% |
| Normalized Basic EPS | -5.48% | 53.68% | 32.17% | 68.05% | 78.01% |
| EPS Diluted | 39.11% | 48.44% | 29.41% | 39.66% | 51.08% |
| Normalized Diluted EPS | -5.48% | 53.68% | 32.17% | 68.05% | 78.01% |
| Average Basic Shares Outstanding | 4.33% | 4.76% | 13.18% | 17.57% | 29.43% |
| Average Diluted Shares Outstanding | 4.33% | 4.76% | 13.18% | 17.57% | 29.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |